Skip to main content
Signal8
Launch Terminal

Beyond Air, Inc. (XAIR)

Beyond Air, Inc. functions as a specialized entity involved in both the development of medical devices and biopharmaceutical solutions. A central part of its operations is the LungFit platform, an innovative system that generates and delivers nitric oxide. Within this platform, LungFit PH is currently available, used to address persistent pulmonary hypertension in infants. Furthermore, the company is advancing LungFit PRO, a product intended for various viral lung ailments like community-acquired viral pneumonia (including COVID-19) and bronchiolitis in hospital settings. It is also creating LungFit GO, which aims to treat nontuberculous mycobacteria infections. The organization adopted its current name, Beyond Air, Inc., in June 2019, having previously been known as AIT Therapeutics, Inc. Its headquarters are situated in Garden City, New York.

Sector: Surgical & Medical Instruments & Apparatus

Industry: Medical - Devices

Beyond Air, Inc. logo

Beyond Air, Inc.

NASDAQ:XAIRHealthcare
-3.03%$2.24
AH$2.20-1.79%vs close
Mkt Cap$2.21M
Float862K
O/S984K
Vol
$ Vol
RVOL
Inst Own8.0%
SI6.9%
Earnings
Dilution
Beyond Air, Inc. logoNASDAQ:XAIR$2.24-3.03%
Phase Distribution
10 lead-sponsored trials·0 active·7 completed
Phase 11
Phase 1/22
Phase 23
Phase 31
Not applicable3
Status Overview
Completed7
Stopped3

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 3
    Completed

    Evaluation of the Efficacy Safety and Tolerability of Nitric Oxide Given Intermittently Via Inhalation to Subjects With Bronchiolitis

    Nitric Oxide

    Bronchiolitis

    Enrollment
    69
    Start
    Mar 2017
    Primary Completion
    Apr 2018
    Completion
    Apr 2018
    NCT03053388
  • Phase 2
    Completed

    Inhaled Nitric Oxide for Patients With MABSC

    Nitric Oxide

    Mycobacterium Abscessus Infection

    Enrollment
    9
    Start
    Jul 2017
    Primary Completion
    May 2018
    Completion
    Apr 2019
    NCT03208764
  • Phase 2
    Completed

    Evaluation of Two Doses of Nitric Oxide (NO) Given Intermittently Via Inhalation to Subjects With Bronchiolitis

    Nitric Oxide

    Bronchiolitis Acute

    Enrollment
    95
    Start
    Nov 2019
    Primary Completion
    Mar 2020
    Completion
    Apr 2020
    NCT04060979
  • Phase 2
    Withdrawn

    Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (CANADA Trial)

    150 ppm Nitric Oxide delivered through LungFit Delivery System, 80 ppm Nitric Oxide delivered through LungFit Delivery System

    COVID-19, SARS-CoV 2 +3

    Enrollment
    0
    Start
    Jul 2020est.
    Primary Completion
    Nov 2020est.
    Completion
    Dec 2020est.
    NCT04456088
  • Phase 1/2
    Completed

    Evaluation of the Safety and Tolerability of Nitric Oxide (NO) Via Inhalation to Subjects With Bronchiolitis

    Nitric Oxide, Placebo

    Bronchiolitis

    Enrollment
    43
    Start
    Jan 2013
    Primary Completion
    Jan 2016
    Completion
    Jan 2016
    NCT01768884
  • Phase 1/2
    Completed

    Evaluation of the Safety and Tolerability of Inhaled Nitric Oxide to Subjects With Cystic Fibrosis

    Nitric oxide

    Cystic Fibrosis

    Enrollment
    9
    Start
    Dec 2013
    Primary Completion
    Nov 2015
    Completion
    Nov 2015
    NCT01958944
  • Phase 1
    Terminated

    A Study to Assess the Safety and Efficacy of UNO - Ultra High Concentration Nitric Oxide Injection in Combination With PD-1 Inhibitors Into Unresectable Solid Primary or Metastatic Tumors

    Nitric Oxide 25,000 ppm, Nitric Oxide 50,000 ppm

    Cancer

    Enrollment
    38
    Start
    Aug 2022
    Primary Completion
    Aug 2025
    Completion
    Aug 2025
    NCT05351502
  • Not applicable
    Terminated

    Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial)

    Nitric Oxide delivered via LungFit™ system

    Corona Virus Infection, COVID-19 +5

    Enrollment
    4
    Start
    Jun 2020
    Primary Completion
    Sep 2020
    Completion
    Sep 2020
    NCT04397692
  • Not applicable
    Completed

    Inhaled NO for the Treatment of Viral Pneumonia in Adults

    LungFit™

    Viral Pneumonia, Nitric Oxide +5

    Enrollment
    40
    Start
    Nov 2020
    Primary Completion
    Aug 2022
    Completion
    Aug 2022
    NCT04606407
  • Not applicable
    Completed

    A Pilot Study to Assess the Effect of Intermittent iNO on the Treatment of NTM Lung Infection in CF and Non-CF Patients

    LungFit

    Non-Tuberculous Mycobacterial Pneumonia, Cystic Fibrosis +3

    Enrollment
    15
    Start
    Dec 2020
    Primary Completion
    Jul 2022
    Completion
    Oct 2022
    NCT04685720
Search ClinicalTrials.gov for “Beyond Air”